hptnHPTN 052 – Site PI: Prof. Johnstone Kumwenda

Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples. 

Visit Website

 

 


 

hptnHPTN 084 – Site PI: Dr. Noel Kayange

A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women.

Visit Website

 

 


 

hvtnHVTN 703 / HPTN 081 – Site PI: Prof. Johnstone Kumwenda

A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection in women in sub-Saharan Africa.

Visit Website

 

 


 

hvtnHPTN 035 – Site PI: Late Prof. Bonus Makanani

Phase II/IIb, four-arm, multisite, randomized controlled trial to evaluate the safety and effectiveness of two candidate vaginal microbicides, BufferGel and 0.5% PRO 2000/5 Gel (P), for the prevention of HIV infection in women.

Visit Website

 

 


 

IMPAACT Logo TransparentBack 0IMPAACT 1077 – Site PI: Late Prof. Bonus Makanani & Dr. Luis Gadama

PROMISE Study – Promoting Maternal and Infant Survival Everywhere

Visit Website

 

 


 

covpnCoVPN 3008 – Site PI: Dr. Noel Kayange

Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern (CoVPN3008)

Visit Website

 

 


 

MTN Logo Stacked LargeMTN 020 – Site PI: Late Dr. George Kafulafula & Late Prof. Bonus Makanani

The power of the shared experience: MTN-020/ASPIRE trial participants’ descriptions of peer influence on acceptability of and adherence to the dapivirine vaginal ring for HIV prevention

Visit Website

 

 


 

actgACTG 5379 – Site PI: Dr. Mulinda Nyirenda

B-Enhancement of HBV vaccinatoin in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B

Visit Website

 

 

 


 

viivPALISADE – Site PI: Dr. Noel Kayange

Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus) (PALISADE)

Visit Website

 

 

 


 

IMPAACT Logo TransparentBack 0IMPAACT 2009 – Site PI: Dr. Frank Taulo & Dr. Sharon Mambiya

Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants

Visit Website